Lineage Cell Therapeutics (LCTX) Non-Current Deferred Tax Liability (2013 - 2026)

Lineage Cell Therapeutics has reported Non-Current Deferred Tax Liability for 12 years, with the latest figure at $22000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability fell 91.94% year-over-year to $22000.0; the trailing twelve-month figure through Mar 2026 stood at $22000.0 (down 91.94% YoY), and the FY2025 full-year result was $22000.0, down 91.94% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $22000.0, roughly flat from $22000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $2.1 million in Q1 2022, with the low at $22000.0 in Q4 2025.
• Historically, Non-Current Deferred Tax Liability has averaged $667705.9 across 5 years, with a median of $273000.0 in 2023.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability surged 132.21% — and 2025, when it plunged 91.94%.
• Lineage Cell Therapeutics' Non-Current Deferred Tax Liability stood at $2.1 million in 2022, then sank by 86.85% to $273000.0 in 2023, then changed by 0.0% to $273000.0 in 2024, then sank by 91.94% to $22000.0 in 2025, then changed by 0.0% to $22000.0 in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $22000.0 (Q1 2026), $22000.0 (Q4 2025), and $273000.0 (Q3 2025), per Business Quant data.